Navigation Links
DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
Date:3/11/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., March 11, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar"), a clinical and commercial stage drug development company with a focus on the treatment of cancer, today announced that Jeffrey Bacha , President & CEO of DelMar, will present at the ROTH 25th Annual Growth Stock Conference in Laguna Niguel, CA at 5:00pm PDT on Monday, March 18th, 2013.

"We are pleased to present the DelMar story at the ROTH Conference," said Jeffrey Bacha .  "This conference will complement our proactive program of investor communications and increase our awareness to the financial community as a new public company."

Mr. Bacha's presentation will be available on line at http://wsw.com/webcast/roth27/dmpi.t/

About DelMar Pharma
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989 or Booke & Company Investor Relations, admin@bookeandco.com.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
2. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
5. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
6. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
7. Pipeline Initiatives, Partnerships to Drive Growth - Research Report on Pfizer, Theravance, ISIS Pharmaceuticals, Infinity Pharmaceuticals and Ironwood
8. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
9. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
10. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
11. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2019)... (PRWEB) , ... October 17, 2019 , ... The findings ... lung illness in the individuals studied could be caused by toxic chemicals rather than ... Severe Pulmonary Illness Associated With E-Cigarette Use (Vaping): A Report of Eight Cases ,” ...
(Date:10/15/2019)... (PRWEB) , ... October 14, ... ... VALIDATE® LP2 linearity and calibration verification kit, for Roche cobas® analyzers, Order ... and Apolipoprotein B (Apo-B). Each VALIDATE® LP2 kit, liquid, ready-to-use, and ...
(Date:10/15/2019)... ... ... Twiggy Bean, Ph.D., wanted to educate others about the divorce bullying epidemic ... and become truly child focused. This objective prompted her to write “Divorce Bullying: An ... Don’t be a divorce bully!” (published by Balboa Press), a guidebook that serves as ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... October 10, 2019 , ... In attendance at this year’s ... hear the significant results of an independent study presented by researchers from the ... study poster entitled “The Acute Effects of Citrulline Malate and Bonded Arginine Silicate ...
(Date:10/8/2019)... ... 2019 , ... What unique insights can three former Surgeons General of the ... the nation? That question will be answered at ICAA 2019: Shaping the Future of ... event will take place October 10-12, 2019, at the Gaylord Palms Resort and Convention ...
(Date:10/8/2019)... ... October 08, 2019 , ... In Vitro Sciences (IVS), ... Fertility Care (AFC), an advanced reproductive services (RE) facility operating in the greater ... RE services to expectant families throughout Arizona and the greater Southwest. , This ...
(Date:10/8/2019)... ... , ... Cognosante has been awarded a contract to continue ... Referrals and Authorizations program. The new task order will allow Cognosante ... enterprise-wide system used by community care staff to generate referrals and authorizations for ...
(Date:10/8/2019)... ... October 08, 2019 , ... As ... samples, Meiqing Shi, associate professor with the University of Maryland Department of Veterinary ... published in Nature Communications, Shi and his lab have discovered a new pathway ...
Breaking Medicine News(10 mins):